- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00584181
High-resolution Computed Tomography (HRCT) Evaluation of Airway Distensibility in Lung Transplant Recipients
High Resolution Computed Tomographic Evaluation of Airway Distensibility in Lung Transplant Recipients: A Pilot Study
Study Overview
Status
Conditions
Detailed Description
Chest CT imaging will be obtained in the radiology department at UTMB. After the initial screening visit, subjects will visit the pulmonary function laboratory where they will undergo spirometry and measurement of lung volumes by whole body plethysmography. Within two hours of pulmonary function testing, subjects will undergo an initial HRCT scan. After the initial HRCT, subjects will inhale a standard dose of ipratropium bromide (0.5 mg) using a hand held nebulizer. Thirty minutes after ipratropium bromide administration, spirometry will be measured followed by a second HRCT scan.
Spirometry measurements will be performed in triplicate with the subjects in a seated position using a portable Koko spirometer (PDS, Louisville, CO). After the spirometry measurements, lung volumes will be measured in a body plethysmograph (MedGraphics, St. Paul, MN) with the subjects in a seated position with a nose clip. Subjects will be instructed to pant against the closed shutter at a frequency of 1-3 Hz. Lung volume measurements will be obtained prior to inital chest CT. Subjects will undergo high resolution computed tomography (HRCT) scanning within 30 minutes of initial lung volume measurements.
After the initial HRCT of the chest, subjects will inhale a dose of nebulized ipratropium bromide (0.5 mg) by standard nebulizer after which spirometry and lung volume measurements will be repeated in the pulmonary function laboratory. Spirometry and lung volume measurements will be performed in the same manner. Lung volume measurements will be obtained to account for changes in lung volumes after bronchodilator administration. Changes in lung volumes will be used to account for any changes noted on HRCT scans.
HRCT scanning will begin 6 cm above the top of the dome of the diaphragm, at TLC and moved caudally. Images will be reconstructed with the use of a high-spatial frequency (resolution) algorithm that enhanced edge detection, at a window level of -450 Hounsfield units and a window width of 1,350 Hounsfield units. We will consider the airway diameters after maximum bronchodilation with ipratropium to be a function principally of the structural characteristics of airways. The TLC measurements after ipratropium will be the best reflection of intrinsic structure. CT airway measurement analysis will be performed by VIDA Diagnostics. We have entered into a collaboration with VIDA Diagnostics that will allow accurate and reliable CT airway measurements. Subject's CT images obtained at UTMB will be deidentified and electronically transmitted to a research collaborator at VIDA Diagnostics located in Coralville, IA. The CT images will have a code assigned, known only to the PI. Using a proprietary software platform, airway measurements will be performed and the data electronically transmitted to the PI at UTMB.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Texas
-
Galveston, Texas, United States, 77555
- University of Texas Medical Branch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- lung transplant recipients >18 years of age
- at least 12 months or greater from time of transplantation
Exclusion Criteria:
- hemodynamic instability
- hypoxemia
- pneumonia
- moderate or large pleural effusion
- clinical evidence of acute rejection
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Lung transplant recipients
Lung transplant recpients enrolled as study subjects will undergo pulmonary function tests (spirometry and lung volume measurements) and initial HRCT of chest.
These subjects will receive nebulized ipratropium followed by pulmonary function tests (spirometry and lung volume measurements) and repeat HRCT.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Spirometry changes
Time Frame: Two hours (before and after inhalation of ipratropium)
|
Assessment of changes in spirometry following inhalation of nebulized ipratropium
|
Two hours (before and after inhalation of ipratropium)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lung volumes
Time Frame: Two hours (before and after inhalation of ipratropium)
|
Assessment of changes in total lung capacity, functional reserve capacity and inspiratory capacity following inhalation of nebulized ipratropium
|
Two hours (before and after inhalation of ipratropium)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Radiographic changes in airway caliber
Time Frame: Two hours (before and after inhalation of ipratropium)
|
Assessment of changes in airway caliber as determined by high resolution chest CT images following inhalation of nebulized ipratropium
|
Two hours (before and after inhalation of ipratropium)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 07-247
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unspecified Complication of Lung Transplant
-
Instituto de Investigacion Sanitaria La FeCompletedUnspecified Complication of Liver TransplantSpain
-
Duke UniversityWithdrawnUnspecified Complication of Bone Marrow TransplantUnited States
-
Northwestern UniversityCompletedDisorder Related to Renal Transplantation | Unspecified Complication of Kidney TransplantUnited States
-
Medical College of WisconsinCompletedCancer | Effects of Chemotherapy | Unspecified Complication of Bone Marrow Transplant | Auto Immune DiseaseUnited States
-
Massachusetts General HospitalCompletedComplication of TransplantUnited States
-
University of CincinnatiUniversity of Colorado, Denver; Children's Hospital Medical Center, CincinnatiCompletedComplication of TransplantUnited States
-
Northwestern UniversityTerminatedComplication of TransplantUnited States
-
Fundación Pública Andaluza para la Investigación...Sociedad Andaluza de Trasplantes de Organos y TejidosCompletedRenal Transplant Rejection | Other Complication of Kidney TransplantSpain
-
University of Witwatersrand, South AfricaCompletedComplication of Surgical and Medical Care, UnspecifiedSouth Africa
-
Assiut UniversityNot yet recruitingLiver Transplant; Complications | Renal Complication of Procedure